CN122440641A - 用氘代jak抑制剂治疗脱毛障碍 - Google Patents

用氘代jak抑制剂治疗脱毛障碍

Info

Publication number
CN122440641A
CN122440641A CN202610044633.5A CN202610044633A CN122440641A CN 122440641 A CN122440641 A CN 122440641A CN 202610044633 A CN202610044633 A CN 202610044633A CN 122440641 A CN122440641 A CN 122440641A
Authority
CN
China
Prior art keywords
compound
day
pharmaceutically acceptable
acceptable salt
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202610044633.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·T·瓦格纳
J·V·卡塞拉
P·B·格雷汉姆
V·布拉曼
V·尤塔姆辛格
J·冯赫恩
C·E·汉密尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industry Co ltd
Original Assignee
Sun Pharmaceutical Industry Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN122440641(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industry Co ltd filed Critical Sun Pharmaceutical Industry Co ltd
Publication of CN122440641A publication Critical patent/CN122440641A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202610044633.5A 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍 Pending CN122440641A (zh)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US62/331,827 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US62/338,869 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US62/418,774 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US62/419,237 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US62/434,404 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US62/466,358 2017-03-02
US201762492758P 2017-05-01 2017-05-01
US62/492,758 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors
CN201780027427.2A CN109069493A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780027427.2A Division CN109069493A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍

Publications (1)

Publication Number Publication Date
CN122440641A true CN122440641A (zh) 2026-07-24

Family

ID=60203616

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202610044633.5A Pending CN122440641A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍
CN202610039132.8A Pending CN121868312A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍
CN201780027427.2A Pending CN109069493A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202610039132.8A Pending CN121868312A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍
CN201780027427.2A Pending CN109069493A (zh) 2016-05-04 2017-05-04 用氘代jak抑制剂治疗脱毛障碍

Country Status (21)

Country Link
US (3) US10561659B2 (cg-RX-API-DMAC7.html)
EP (2) EP4424367A3 (cg-RX-API-DMAC7.html)
JP (3) JP7145080B2 (cg-RX-API-DMAC7.html)
KR (3) KR20190003711A (cg-RX-API-DMAC7.html)
CN (3) CN122440641A (cg-RX-API-DMAC7.html)
AU (3) AU2017261286B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072339A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022519A1 (cg-RX-API-DMAC7.html)
DK (1) DK3452039T3 (cg-RX-API-DMAC7.html)
ES (1) ES2988629T3 (cg-RX-API-DMAC7.html)
FI (1) FI3452039T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241345T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068643T2 (cg-RX-API-DMAC7.html)
LT (1) LT3452039T (cg-RX-API-DMAC7.html)
MX (6) MX388054B (cg-RX-API-DMAC7.html)
PL (1) PL3452039T3 (cg-RX-API-DMAC7.html)
PT (1) PT3452039T (cg-RX-API-DMAC7.html)
RS (1) RS66006B1 (cg-RX-API-DMAC7.html)
SI (1) SI3452039T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400389T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017192905A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561659B2 (en) * 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) * 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) * 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US12643902B2 (en) 2020-08-12 2026-06-02 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched substituted pyrrolo[2,3-d]pyrimidines
US20220213105A1 (en) 2020-08-12 2022-07-07 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
US20230390292A1 (en) * 2020-10-28 2023-12-07 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
AU2022328282A1 (en) 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
US20260027120A1 (en) * 2024-07-25 2026-01-29 Sun Pharmaceutical Industries, Inc. Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
PT2635299T (pt) * 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
KR102242077B1 (ko) * 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
MX2016010213A (es) * 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
EP4424367A3 (en) 2024-11-13
JP2019516684A (ja) 2019-06-20
MX388054B (es) 2025-03-19
JP7586868B2 (ja) 2024-11-19
EP3452039A4 (en) 2019-12-25
AU2017261286B2 (en) 2023-03-23
SI3452039T1 (sl) 2024-12-31
JP2025026895A (ja) 2025-02-26
MX2023002325A (es) 2023-03-22
EP4424367A2 (en) 2024-09-04
AU2017261286A1 (en) 2018-11-22
AU2023201112B2 (en) 2025-05-08
JP7145080B2 (ja) 2022-09-30
US20200222408A1 (en) 2020-07-16
KR20190003711A (ko) 2019-01-09
US10561659B2 (en) 2020-02-18
US20240423986A1 (en) 2024-12-26
ES2988629T3 (es) 2024-11-21
HUE068643T2 (hu) 2025-01-28
KR102810262B1 (ko) 2025-05-19
PL3452039T3 (pl) 2024-11-18
EP3452039B1 (en) 2024-07-03
CA3022519A1 (en) 2017-11-09
LT3452039T (lt) 2024-10-25
BR112018072339A2 (pt) 2019-02-19
MX2023002323A (es) 2023-03-22
FI3452039T3 (fi) 2024-10-02
JP2022171838A (ja) 2022-11-11
DK3452039T3 (da) 2024-10-07
MX2021014175A (es) 2022-01-04
AU2025213576A1 (en) 2025-08-21
MX2018013347A (es) 2019-09-02
MX2023002321A (es) 2023-03-22
HRP20241345T1 (hr) 2024-12-20
AU2023201112A1 (en) 2023-03-30
PT3452039T (pt) 2024-10-07
KR20250070139A (ko) 2025-05-20
KR20230086814A (ko) 2023-06-15
MX2023002324A (es) 2023-03-22
CN109069493A (zh) 2018-12-21
WO2017192905A1 (en) 2017-11-09
CN121868312A (zh) 2026-04-17
SMT202400389T1 (it) 2024-11-15
US20190160068A1 (en) 2019-05-30
US12076323B2 (en) 2024-09-03
EP3452039A1 (en) 2019-03-13
RS66006B1 (sr) 2024-10-31

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination